Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109
administered by intravitreal injection to reduce the progression of subretinal fibrosis in
subjects with advanced neovascular age-related macular degeneration (NVAMD).